<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796272</url>
  </required_header>
  <id_info>
    <org_study_id>20CH032</org_study_id>
    <secondary_id>2020-A00841-38</secondary_id>
    <nct_id>NCT04796272</nct_id>
  </id_info>
  <brief_title>Role of Individualized Versus Traditional Exercise in Combating Fatigue in Fatigued Multiple Sclerosis Patients</brief_title>
  <acronym>REEN-SEP</acronym>
  <official_title>Role of Individualized Versus Traditional Exercise in Combating Fatigue in Fatigued Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project will be to characterise the benefits of an exercise programme&#xD;
      adapted to each individual's abilities compared to a traditional exercise programme with the&#xD;
      aim of reducing perceived fatigue and improving the quality of life of Patients with multiple&#xD;
      sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic fatigue is a very common symptom reported (80%) by patients with multiple sclerosis&#xD;
      (MS), regardless of the type of MS and level of disability. Despite the clinical importance&#xD;
      of MS-related fatigue, pharmacological treatments remain quite ineffective in preventing or&#xD;
      treating chronic fatigue.&#xD;
&#xD;
      Recently, physical activity has proven to be an effective therapy with benefits on chronic&#xD;
      fatigue as well as on different functions (muscular, cardiorespiratory, cognitive, etc.).&#xD;
      Nevertheless, the effects of physical exercise may vary between MS patients, as MS is a&#xD;
      heterogeneous disease and does not affect each individual in the same way. The objective of&#xD;
      this project will be to characterise the benefits of an exercise programme adapted to each&#xD;
      individual's abilities compared to a traditional exercise programme with the aim of reducing&#xD;
      perceived fatigue and improving the quality of life of Patients with multiple sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic fatigue score</measure>
    <time_frame>Month 3</time_frame>
    <description>assessed using the Fatigue Severity Scale (FSS) questionnaire before and after an individualized re-training program compared to a traditional re-training program in MS patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiorespiratory fitness</measure>
    <time_frame>Month 3</time_frame>
    <description>evaluated by measuring the maximum oxygen consumption (VO2max) during an incremental exercise on a cycloergometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological parameters</measure>
    <time_frame>Month 3</time_frame>
    <description>red blood cell and hemoglobin levels measured by spectrophotometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>Month 3</time_frame>
    <description>c-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of sleep</measure>
    <time_frame>Month 3</time_frame>
    <description>actigraphy measurements and sleep diary records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical activation level</measure>
    <time_frame>Month 3</time_frame>
    <description>transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortico-spinal excitability</measure>
    <time_frame>Month 3</time_frame>
    <description>transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuromuscular fatigue of peripheral function</measure>
    <time_frame>Month 3</time_frame>
    <description>electrical nerve stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis overall quality of life : Fatigue questionnaire</measure>
    <time_frame>Month 3</time_frame>
    <description>Fatigue questionnaire by Modified Fatigue Impact Scale (MFIS) results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis overall quality of life :Quality of Life</measure>
    <time_frame>Month 3</time_frame>
    <description>Quality of Life Questionnaire by SEP-59 results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis overall quality of life :Depression</measure>
    <time_frame>Month 3</time_frame>
    <description>Depression Questionnaire by Center for Epidemiologic Studies Depression (CES-D) results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis overall quality of life : Sleep Quality</measure>
    <time_frame>Month 3</time_frame>
    <description>Sleep Quality Questionnaire by Pittsburgh Sleep Quality Index (PSQ-I) results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis overall quality of life : Physical Activity</measure>
    <time_frame>Month 3</time_frame>
    <description>Physical Activity Questionnaire by Godin Leisure-Time Exercise Questionnaire (GLTEQ) results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Traditional exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fatigued multiple sclerosis patients with a traditional training program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individual exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tired multiple sclerosis patients with an adapted and individualized training program</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adapted and individualized physical training program</intervention_name>
    <description>Physical training program adapted and individualized according to each patient in this group</description>
    <arm_group_label>Individual exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>traditional training program</intervention_name>
    <description>Same training program for all patients in this group</description>
    <arm_group_label>Traditional exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 70 years old&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  With relapsing-remitting multiple sclerosis (RRMS) as defined by McDonald's 2010&#xD;
             criteria.&#xD;
&#xD;
          -  Between 2 and 25 years from the onset of multiple sclerosis&#xD;
&#xD;
          -  With a high level of fatigue, corresponding to a score of Fatigue Severity Scale&gt; 4&#xD;
             and Fatigue questionnaire &gt; 38.&#xD;
&#xD;
          -  Expanded Disability Status Scale Score 5&#xD;
&#xD;
          -  Testing â‰¥ 4 in all leg muscles.&#xD;
&#xD;
          -  Ability to walk for 10 minutes without stopping (self-reported)&#xD;
&#xD;
          -  Affiliates or beneficiaries of a social security scheme&#xD;
&#xD;
          -  Having freely given their written consent after having been informed of the purpose,&#xD;
             course of action and potential risks involved&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cerebellar spasticity or ataxia in either leg.&#xD;
&#xD;
          -  Abnormal range of motion of the toes and/or ankle.&#xD;
&#xD;
          -  Musculoskeletal injury that interferes with pedaling.&#xD;
&#xD;
          -  High resting heart rate (&gt;90 beats per minute).&#xD;
&#xD;
          -  Blood pressure &gt; 144/94 mmHg.&#xD;
&#xD;
          -  Onset of a multiple sclerosis attack within 90 days prior to the study.&#xD;
&#xD;
          -  Recent adjustment of any medication or drugs that may impact on fatigue, or taking&#xD;
             stimulants for fatigue (e.g. Modafinil).&#xD;
&#xD;
          -  Taking of neuro-active substances that may impair cortico-spinal excitability&#xD;
             (hypnotics, antiepileptics, psychotropic drugs, muscle relaxants) throughout the study&#xD;
             period.&#xD;
&#xD;
          -  Contraindication to the application of a magnetic field&#xD;
&#xD;
          -  History of co-morbid disease or conditions that would compromise the subject's safety&#xD;
             during the study.&#xD;
&#xD;
          -  Participation at the same time in another medical intervention study or having&#xD;
             participated in such a study within 30 days prior to this study.&#xD;
&#xD;
          -  Pregnant and Nursing Women&#xD;
&#xD;
          -  Women of childbearing age without effective contraception&#xD;
&#xD;
          -  Patient unable to understand the purpose and conditions of the study, incapable of&#xD;
             giving consent&#xD;
&#xD;
          -  Patient deprived of liberty or patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Philippe CAMDESSANCHE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Philippe CAMDESSANCHE, MD PhD</last_name>
    <phone>(0)477820559</phone>
    <phone_ext>+33</phone_ext>
    <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine BAUDOT, CRA</last_name>
    <phone>(0)477829450</phone>
    <phone_ext>+33</phone_ext>
    <email>amandine.baudot@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Philippe CAMDESSANCHE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence ROBERT-VARVAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud LACOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure MAZZOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MÃ©lanie FORESTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LÃ©onard FEASSON, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>individual exercise</keyword>
  <keyword>fatigue</keyword>
  <keyword>traditional exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

